Novel Biomarkers to Distinguish between Type 3c and Type 2 Diabetes Mellitus by Untargeted Metabolomics
Pancreatogenic diabetes mellitus (T3cDM) is a highly frequent complication of pancreatic disease, especially chronic pancreatitis, and it is often misdiagnosed as type 2 diabetes mellitus (T2DM). A correct diagnosis allows the appropriate treatment of these patients, improving their quality of life, and various technologies have been employed over recent years to search for specific biomarkers of each disease. The main aim of this metabolomic project was to find differential metabolites between T3cDM and T2DM. Reverse-phase liquid chromatography coupled to high-resolution mass spectrometry was performed in serum samples from patients with T3cDM and T2DM. Multivariate Principal Component and Partial Least Squares-Discriminant analyses were employed to evaluate between-group variations. Univariate and multivariate analyses were used to identify potential candidates and the area under the receiver-operating characteristic (ROC) curve was calculated to evaluate their diagnostic value. A panel of five differential metabolites obtained an area under the ROC curve of 0.946. In this study, we demonstrate the usefulness of untargeted metabolomics for the differential diagnosis between T3cDM and T2DM and propose a panel of five metabolites that appear altered in the comparison between patients with these diseases.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
---|---|
Enthalten in: |
Metabolites - 10(2020), 11 vom: 22. Okt. |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Jimenez-Luna, Cristina [VerfasserIn] |
---|
Links: |
---|
Themen: |
Biomarker |
---|
Anmerkungen: |
Date Revised 27.11.2020 published: Electronic Citation Status PubMed-not-MEDLINE |
---|
doi: |
10.3390/metabo10110423 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM31674428X |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM31674428X | ||
003 | DE-627 | ||
005 | 20231225161737.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/metabo10110423 |2 doi | |
028 | 5 | 2 | |a pubmed24n1055.xml |
035 | |a (DE-627)NLM31674428X | ||
035 | |a (NLM)33105675 | ||
035 | |a (PII)E423 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Jimenez-Luna, Cristina |e verfasserin |4 aut | |
245 | 1 | 0 | |a Novel Biomarkers to Distinguish between Type 3c and Type 2 Diabetes Mellitus by Untargeted Metabolomics |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Revised 27.11.2020 | ||
500 | |a published: Electronic | ||
500 | |a Citation Status PubMed-not-MEDLINE | ||
520 | |a Pancreatogenic diabetes mellitus (T3cDM) is a highly frequent complication of pancreatic disease, especially chronic pancreatitis, and it is often misdiagnosed as type 2 diabetes mellitus (T2DM). A correct diagnosis allows the appropriate treatment of these patients, improving their quality of life, and various technologies have been employed over recent years to search for specific biomarkers of each disease. The main aim of this metabolomic project was to find differential metabolites between T3cDM and T2DM. Reverse-phase liquid chromatography coupled to high-resolution mass spectrometry was performed in serum samples from patients with T3cDM and T2DM. Multivariate Principal Component and Partial Least Squares-Discriminant analyses were employed to evaluate between-group variations. Univariate and multivariate analyses were used to identify potential candidates and the area under the receiver-operating characteristic (ROC) curve was calculated to evaluate their diagnostic value. A panel of five differential metabolites obtained an area under the ROC curve of 0.946. In this study, we demonstrate the usefulness of untargeted metabolomics for the differential diagnosis between T3cDM and T2DM and propose a panel of five metabolites that appear altered in the comparison between patients with these diseases | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a biomarker | |
650 | 4 | |a chronic pancreatitis | |
650 | 4 | |a diagnosis | |
650 | 4 | |a metabolomics | |
650 | 4 | |a pancreatogenic diabetes mellitus | |
650 | 4 | |a type 2 diabetes mellitus | |
650 | 4 | |a untargeted LC-HRMS | |
700 | 1 | |a Martin-Blazquez, Ariadna |e verfasserin |4 aut | |
700 | 1 | |a Dieguez-Castillo, Carmelo |e verfasserin |4 aut | |
700 | 1 | |a Diaz, Caridad |e verfasserin |4 aut | |
700 | 1 | |a Martin-Ruiz, Jose Luis |e verfasserin |4 aut | |
700 | 1 | |a Genilloud, Olga |e verfasserin |4 aut | |
700 | 1 | |a Vicente, Francisca |e verfasserin |4 aut | |
700 | 1 | |a Del Palacio, Jose Perez |e verfasserin |4 aut | |
700 | 1 | |a Prados, Jose |e verfasserin |4 aut | |
700 | 1 | |a Caba, Octavio |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Metabolites |d 2011 |g 10(2020), 11 vom: 22. Okt. |w (DE-627)NLM220344280 |x 2218-1989 |7 nnns |
773 | 1 | 8 | |g volume:10 |g year:2020 |g number:11 |g day:22 |g month:10 |
856 | 4 | 0 | |u http://dx.doi.org/10.3390/metabo10110423 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 10 |j 2020 |e 11 |b 22 |c 10 |